Table 1

Demographic characteristics of the participants

CharacteristicsTotal
(n=549)
No vaccination
(n=87)
COVID-19 vaccination
(n=462)
P value
Demographics
 Age (years), mean (SD)/median (IQR)41.01 (12.65)/39 (32–49)40.75 (14.50)/37 (28–52.5)41.05 (12.36)/39.5 (32–48)0.86
 Male sex, n (%)531 (96.7)82 (94.3)449 (97.2)0.18
 Body mass index (kg/m²), mean (SD)27.55 (4.06)26.95 (3.59)27.67 (4.15)0.15
 Completed college (n, %)358 (65.2)50 (57.5)308 (66.7)0.81
 Smoking, n (%)0.08
 Never286 (52.1)44 (50.6)242 (52.4)
 Sometimes74 (13.5)10 (11.5)64 (13.9)
 Regular114 (20.8)26 (29.9)88 (19.1)
 Quit75 (13.7)7 (8.5)68 (14.7)
 Alcohol drinking, n (%)0.37
 Never130 (23.7)19 (21.8)111 (24.0)
 Sometimes259 (47.2)42 (48.3)217 (47.0)
 Regular80 (14.6)17 (19.5)63 (13.6)
 Quit80 (14.6)9 (10.3)71 (15.4)
 Comorbidities*, n (%)274 (49.9)40 (46.0)234 (50.7)0.48
COVID-19 vaccination
 Vaccination, n (%)462 (84.2)
 Completed400 (86.6)
 Not completed62 (13.4)
 Vaccination received, n (%)
 Sinovac Life250 (54.1)250 (54.1)
 Sinopharm BIBP174 (37.7)174 (37.7)
 Others38 (8.2)38 (8.2)
Gout specific indicators
 Age at onset (years), mean (SD)35.90 (11.1)35.57 (13.7)35.97 (10.5)0.81
 Duration of gout (years), mean (SD)6.64 (5.5)7.74 (6.3)6.40 (5.3)0.11
 Positive family history, n (%)101 (18.4)14 (16.1)87 (18.8)0.55
 Palpable tophus, n (%)66 (12.0)8 (9.2)58 (12.6)0.38
 Gout impact scale scores†, mean (SD)
 Gout concern overal82.62 (22.36)82.54 (20.60)82.63 (22.7)0.97
 Gout concern during attack gout71.65 (20.55)73.61 (19.96)71.29 (20.66)0.33
 Medications side effects71.47 (19.9)72.72 (19.22)71.23 (20.03)0.52
 Unmet gout treatment need60.93 (15.82)62.45 (16.76)60.64 (15.63)0.33
 Well-being during attack58.27 (25.88)63.43 (23.65)57.30 (26.18)0.04
 Colchicine prophylaxis, n (%)142 (25.9)28 (32.2)114 (24.7)0.14
 Achieving the treatment urate target in recent year, n (%)‡141 (25.7)26 (29.9)115 (24.9)0.35
 Last serum urate done before first vaccine (mg/dL), mean (SD)7.51 (2.01)7.63 (2.22)7.45 (1.97)0.55
 Gout flares per person within last 3 months before first vaccine, mean0.560.560.56
 Gout flares within last 3 months after any vaccine, n (%)231 (41.1)28 (32.2)203 (43.9)0.04
 Urate-lowering drugs use at the time of the first vaccine, n (%)0.44
 Febuxostat304 (55.4)53 (60.9)251 (54.3)
 Benzbromarone48 (8.6)8 (9.2)40 (8.7)
 No or missing197 (35.9)26 (29.9)171 (37.0)
  • *Comorbidities include diabetes, hypertension, renal disease, hyperlipidemia, tumour, fracture, cardiovascular, digestive, respiratory or mental diseases.

  • †Gout impact scale scores: 0~100 where 100 indicates worse condition.

  • ‡Achieving the treatment urate target in recent year indicates serum urate < 6 mg/dL.